.Pharmacolibrary.Drugs.ATC.J.J01CA17

Information

Temocillin is a narrow-spectrum, beta-lactamase-resistant penicillin antibiotic. It is primarily used for treating infections caused by Gram-negative bacteria, including Enterobacteriaceae that produce extended-spectrum beta-lactamases (ESBLs). Temocillin is not active against Gram-positive organisms or non-fermenters like Pseudomonas aeruginosa. It is approved in some European countries but is not widely used globally.

Pharmacokinetics

PK parameters were determined in healthy adult volunteers after a single intravenous bolus administration.

References

1. Ngougni Pokem, P, et al., & Laterre, PF (2022). Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. Antibiotics (Basel, Switzerland) 11(7) –. DOI:10.3390/antibiotics11070898 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35884152

2. De Jongh, R, et al., & Carryn, S (2008). Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. The Journal of antimicrobial chemotherapy 61(2) 382–388. DOI:10.1093/jac/dkm467 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18070831

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)